Eloquent-2: A phase 3, randomized, open-label study of lenalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma
Author(s): ,
Meletios Dimopoulos
Affiliations:
National and Kapodistrian University of Athens,Athens,Greece
,
Sagar Lonial
Affiliations:
Winship Cancer Institute,Emory University School of Medicine,Atlanta,United States
,
Antonio Palumbo
Affiliations:
A.O.U. San Giovanni Battista di Torino - Ospedale Molinette,Torino,Italy
,
Darrell White
Affiliations:
QEII Health Science Center and Dalhousie University,Halifax,Canada
,
Sebastian Grosicki
Affiliations:
Silesian Medical University,Katowice,Poland
,
Ivan Spicka
Affiliations:
Charles University Hospital,Prague,Czech Republic
,
Adam Walter-Croneck
Affiliations:
Medical University of Lublin,Lublin,Poland
,
Philippe Moreau
Affiliations:
University Hospital,Nantes,France
,
Maria-Victoria Mateos
Affiliations:
University Hospital of Salamanca-IBSAL,Salamanca,Spain
,
Hila Magen
Affiliations:
Davidoff Cancer Center, Rabin Medical Center,Petah Tikva,Israel;Tel Aviv University,Ramat Aviv,Israel
,
Andrew Belch
Affiliations:
Cross Cancer Institute and University of Alberta,Edmonton,Canada
,
Donna Reece
Affiliations:
Princess Margaret Hospital,Toronto,Canada
,
Meral Beksac
Affiliations:
Ankara University,Ankara,Turkey
,
Andrew Spencer
Affiliations:
Alfred Health-Monash University,Melbourne,Australia
,
Heather Oakervee
Affiliations:
Barts and the London NHS Trust,London,United Kingdom
,
Masafumi Taniwaki
Affiliations:
Kyoto Prefectural University of Medicine,Kyoto,Japan
,
Christoph Röllig
Affiliations:
Universitatsklinikum der TU,Dresden,Germany
,
Ka Lung Wu
Affiliations:
ZNA Stuivenberg,Antwerp,Belgium
,
Anil Singhal
Affiliations:
AbbVie Biotherapeutics Inc. (ABR),Redwood City,United States
,
Jesus San Miguel
Affiliations:
Clinical Universidad de Navarra,Pamplona,Spain
,
Morio Matsumoto
Affiliations:
Nishigunma National Hospital,Shibukawa,Japan
,
Jessica Katz
Affiliations:
Bristol-Myers Squibb,Princeton,United States
,
Eric Bleickardt
Affiliations:
Bristol-Myers Squibb,Wallingford,United States
,
Valerie Poulart
Affiliations:
Bristol-Myers Squibb,Braine-l'Alleud,Belgium
Paul Richardson
Affiliations:
Dana-Farber Cancer Institute,Boston,United States
EHA Learning Center. Dimopoulos M. Jun 12, 2015; 103089
Topic: 3Ec Plasma cell myeloma (Multiple myeloma)
Disclosure(s): Consultancy fees, honoraria and travel costs from Celgene, Janssen and Onyx, Consultancy fees from Novartis, research funding from Genesis and Janssen-Cilag
Prof. Dr. Meletios A Dimopoulos
Prof. Dr. Meletios A Dimopoulos

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: S471

Type: Presidential Symposium

Presentation during EHA20: From 12.06.2015 15:45 to 12.06.2015 17:00

Location: Room A2 3

Background
Elotuzumab, an immunotherapeutic monoclonal antibody (mAb), recognizes Signaling Lymphocytic Activation Molecule F7 (SLAMF7), a protein highly expressed on myeloma cells and natural killer cells. Elotuzumab targets and kills SLAMF7-expressing myeloma cells by direct activation of natural killer cells with minimal effect on normal tissues. Elotuzumab showed encouraging activity with lenalidomide/dexamethasone (Ld) in a Phase 1b/2 study in patients with relapsed/refractory multiple myeloma (RRMM).

Aims
ELOQUENT-2, a Phase 3 study (NCT01239797) compared efficacy and safety of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld.

Methods
Patients with RRMM and 1%u20133 prior therapies were randomized 1:1 to ELd or Ld in 28-day cycles until disease progression or unacceptable toxicity: elotuzumab (10 mg/kg IV) was given weekly during Cycles 1 and 2 and then biweekly; lenalidomide (25 mg) was given on Days 1%u201321; dexamethasone was given weekly (40 mg or 28 mg PO 8 mg IV on elotuzumab dosing weeks). Written informed consent was obtained for all patients. Response/progression was assessed by an independent review committee using European Group for Blood and Bone Marrow Transplant criteria. Primary endpoints were progression-free survival (PFS) and overall response rate (ORR). Results of a prespecified interim analysis are reported.

Results
646 RRMM patients were randomized (321 to ELd, 325 to Ld; median age 66 years [20% of patients %u226575 years old]; refractory to last therapy 35%). Median number of prior therapies was 2, including bortezomib 70%, thalidomide 48% and lenalidomide 6%. High-risk patients were included: del(17p) in 32%; t(4;14) in 9%. At the data cut-off (4 Nov 2014), 35% (ELd arm) and 21% (Ld arm) of patients remained on therapy; discontinuation was mainly due to disease progression (42% in the ELd arm, 47% in the Ld arm). Median number of cycles was 19 and 14 in the ELd and Ld arms, respectively. After a median follow-up of 24 months, PFS rate was superior in the ELd over the Ld arm: 68% vs 57% at 1 year and 41% vs 27% at 2 years. Hazard ratio for PFS was 0.70 (95% CI 0.57, 0.85; p=0.0004). Median (95% CI) PFS in the ELd arm was 19.4 (16.6, 22.2) months vs 14.9 (12.1, 17.2) months in the Ld arm (Figure). PFS benefit with ELd was consistent across key subgroups. ORR (95% CI) was 79% (74, 83) in the ELd arm vs 66% (60, 71) in the Ld arm (p=0.0002). Very good partial response or better was seen in 32.7% and 28.0% of patients in the ELd and Ld arms, respectively; partial response was seen in 45.8% and 37.5%, respectively. Grade 3%u20134 adverse events in %u226515% of patients include neutropenia (25% in the ELd arm, 33% in the Ld arm) and anemia (15% in the ELd arm, 16% in the Ld arm). Infections (any grade) occurred in 81% of patients in the ELd arm and 74% in the Ld arm. Exposure-adjusted infection rates were the same in both arms (incidence rate/100 person-years of exposure, 197). Infusion reactions occurred in 10% of patients with ELd (mostly Grade 1%u20132). There were 210 deaths (94 in the ELd arm, 116 in the Ld arm).

Summary
This is the first positive randomized Phase 3 trial with an immunotherapeutic mAb, assessing Ld with or without elotuzumab in RRMM. It showed a 30% reduction in risk of progression or death with ELd vs Ld. More patients remain on ELd vs Ld, and follow-up for long-term outcomes is ongoing. Infusion reactions were manageable. Elotuzumab, a mAb with a novel mechanism of action, showed improved PFS at 1 year and 2 years, with minimal added toxicity in combination with Ld vs Ld alone in patients with multiple myeloma.

%u2020Equal contribution: M Dimopoulos and S Lonial



Keyword(s): Monoclonal antibody, Multiple myeloma, Refractory, Relapse

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings